{"id":"intravenous-immuneglobulin","safety":{"commonSideEffects":[{"rate":"5–15%","effect":"Headache"},{"rate":"5–10%","effect":"Fever"},{"rate":"5–10%","effect":"Chills"},{"rate":"5–10%","effect":"Myalgia"},{"rate":"3–8%","effect":"Nausea"},{"rate":"5–15%","effect":"Infusion reactions"},{"rate":"<1%","effect":"Aseptic meningitis"},{"rate":"<1%","effect":"Thromboembolism"},{"rate":"<1%","effect":"Acute kidney injury"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IVIG is a blood product containing immunoglobulins (primarily IgG) extracted from the plasma of thousands of healthy donors. It works through multiple mechanisms: providing immediate passive antibody protection against infections, blocking pathogenic autoantibodies, modulating complement activation, and regulating T and B cell function. It is used both for immunodeficiency replacement and as an immunomodulatory agent in autoimmune and inflammatory conditions.","oneSentence":"Intravenous immunoglobulin (IVIG) provides passive immunity by delivering pooled antibodies from multiple donors to neutralize pathogens and modulate immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:43.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders"},{"name":"Secondary immunodeficiency (e.g., in hematologic malignancies)"},{"name":"Autoimmune conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome)"},{"name":"Chronic inflammatory demyelinating polyneuropathy (CIDP)"},{"name":"Kawasaki disease"}]},"trialDetails":[{"nctId":"NCT00659386","phase":"PHASE1","title":"IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2009-02","conditions":"Heart Failure","enrollment":40},{"nctId":"NCT00306033","phase":"PHASE3","title":"Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2004-03","conditions":"Myasthenia Gravis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intravenous ImmuneGlobulin","genericName":"Intravenous ImmuneGlobulin","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravenous immunoglobulin (IVIG) provides passive immunity by delivering pooled antibodies from multiple donors to neutralize pathogens and modulate immune responses. Used for Primary immunodeficiency disorders, Secondary immunodeficiency (e.g., in hematologic malignancies), Autoimmune conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}